An experienced, inspirational oncology drug hunter with deep understanding of small molecule and biologics drug discovery. Helped to bring many new drugs into clinical trials, including a key contributor to the nomination of 13 candidate drugs (CDs) and >10 investigational new drugs (INDs), and 2 launched drugs, Imfinzi® (PD-L1) and Imjudo® (CTLA-4).An authentic leader with a passion for building and leading high-functioning teams/organisations doing groundbreaking cancer research and drug discovery. Strong communicator with a proven ability to influence broadly at all levels, driving innovation and raising scientific quality whilst promoting a culture of trust and mutual integrity.A pioneer in Immuno-oncology (IO) drug discovery, at AstraZeneca/MedImmune proposed PD-L1 as a T cell checkpoint target and devised the drug discovery plan. Since the first approval in 2017, more than 150,000 patients have been treated with Imfinzi®. A core contributor of multiple other IO discovery programs, including Volrustomig (formerly MEDI5752) a bispecific antibody targeting PD1/CTLA-4, currently in Phase III. Recently, conceived AstraZeneca's NextGen IO scientific vision, led the global NextGen IO unit and translated its strategy into action, establishing a sustainable NextGen discovery pipeline.A track record of identifying and implementing novel drug platforms, spanning small molecules (antineoplastic kinase inhibitors, TLR agonists), fusion protein, mono- and bispecific antibodies, antibody-drug conjugates (ADCs), mRNA, and oncolytic virotherapy.An expert scientist in cancer biology, immunology, and drug discovery/translation having presented at national and international scientific meetings and been a co-author on over 85 peer-reviewed publications.